Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in

As Q1 earnings roll in, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least partly on novel assets for obesity.